Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from Oxford University's Department of Paediatrics have successfully completed the first human trial of a vaccine for a common virus that is particularly dangerous to infants.

After fifty years of failed attempts around the world, a vaccine for respiratory syncytial virus (RSV), a major cause of respiratory disease, may now be within sight. The vaccine was conceived and initially tested in animals by a team of scientists at Italian biotechnology firm Okairos (now Reithera Srl), working with the UK’s Pirbright Institute. The results are published in journal Science Translational Medicine.

RSV kills around 200,000 people worldwide each year. Both the elderly and infants are especially vulnerable to developing severe disease with RSV. Two-thirds of babies are infected with RSV before their first birthday and in winter the virus causes annual epidemics resulting in up to 15 out of every 100 admissions to children’s wards. In the world’s poorer areas, RSV is second only to malaria as a killer of children aged under 12 months.

Oxford University's Professor Andrew Pollard leads the Oxford Vaccine Group, which led the clinical trial of the vaccine. He said: 'RSV causes a lot of emergency admissions, especially in babies, and there is currently no way to prevent it. That means it is a priority for vaccine development.'

Dr Christopher Green, the lead physician for the trial, added: 'The results of this trial are a positive signal that prevention of RSV is achievable and follows years of RSV vaccine research at Oxford University and by vaccine manufacturers. The important results of this trial should be dedicated to the members of the public who were willing to be the first to receive the vaccines.'

The Oxford Vaccine Group, working with Reithera Srl, developed what is known as a 'prime-boost viral-vectored' RSV vaccine. The vaccine has two components: the first vaccine primes the immune system, while the second vaccine boosts it. Each component was created by modifying other viruses to carry proteins from RSV. These viral vectors are adapted so that the carrier virus (the vector) cannot replicate to cause disease, and the RSV element, while it triggers an immune response, cannot cause an RSV infection either.

The vectors were a chimpanzee adenovirus called PanAd3, never used in humans before, and a pox virus called modified vaccinia Ankara (MVA). Similar chimpanzee adenovirus vectors and MVA had already been tested as other viral vectored vaccines for other infectious diseases, including the new Ebola vaccines, and have been found to be safe.

This initial trial checked whether the vaccine was safe and immunogenic – whether it caused an immune response. Forty-two healthy adult volunteers received the two components with varying intervals between each element. While the boost component was given as an injection, half of the volunteers received the prime element as an injection and half as a nasal spray.

Professor Pollard said: 'Both components of the vaccine were found to be safe and to create an immune response.

'While I am delighted with these results, this was just a first trial. We need this vaccine for children and the elderly and that is where the efforts in vaccine development will now focus.'

The results of the trial are published in journal Science Translational Medicine on Wednesday 12 August 2015: Chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

 

Similar stories

Human challenge trial launches to study immune response to COVID-19

COVID-19 Vaccinology

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Alternating vaccines trial expands to include two additional vaccines

COVID-19 Clinical Trials Vaccinology

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19 Vaccinology

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

COVID-19 Vaccinology

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

COVID-19 Vaccinology

- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments Vaccinology

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.